The ovarian hormones estrogen and progesterone are master regulators of the development
and function of a broad spectrum of human tissues, including the breast, reproductive and …

Selective progesterone receptor modulators (SPRMs) are a new class of compounds
developed to target the progesterone receptor (PR) with a mix of agonist and antagonist …

Progesterone and progesterone receptors (PR) have a storied albeit controversial history in
breast cancers. As endocrine therapies for breast cancer progressed through the twentieth …

The progesterone receptor (PR) modulates estrogen receptors α (ERα) action in breast
cancer; it is an upregulated target gene of ER, and its expression is dependent on estrogen …

Seventy per cent of breast cancers are luminal carcinomas that express alpha estrogen
receptors (ER). For several decades, its expression has been used as a therapeutic target in …

Steroid hormone receptors (SRs) have a multitude of functions in human biology and
disease progression. The SR family of related ligand-activated transcription factors includes …

Breast cancer progression involves intricate interactions between cancer cells and the tumor
microenvironment (TME). This study elucidates the critical role of progesterone receptor …

Progression to hormone‐independent growth leading to endocrine therapy resistance
occurs in a high proportion of patients with estrogen receptor alpha (ERα) and progesterone …

Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast
carcinomas that express higher levels of progesterone receptor isoform A (PRA) than …

Major roadblocks to developing effective progesterone receptor (PR)-targeted therapies in
breast cancer include the lack of highly-specific PR modulators, a poor understanding of the …